NTRA – Natera, Inc.
NTRA — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
3.63
Margin Of Safety %
-41
Put/Call OI Ratio
1.04
EPS Next Q Diff
0.22
EPS Last/This Y
-0.19
EPS This/Next Y
1.5
Price
322.42
Target Price
315.19
Analyst Recom
1.42
Performance Q
46.53
Upside
-114.9%
Beta
1.5
Ticker: NTRA
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | NTRA | 271.14 | 0.72 | 0.11 | 33287 |
| 2026-07-14 | NTRA | 272.82 | 0.72 | 0.81 | 33547 |
| 2026-07-15 | NTRA | 277.44 | 0.72 | 0.87 | 33579 |
| 2026-07-16 | NTRA | 269.83 | 0.72 | 0.21 | 33579 |
| 2026-07-17 | NTRA | 271.48 | 0.73 | 0.05 | 33195 |
| 2026-07-20 | NTRA | 262.53 | 0.79 | 3.59 | 27009 |
| 2026-07-21 | NTRA | 267.44 | 0.80 | 0.29 | 27253 |
| 2026-07-22 | NTRA | 264.12 | 0.82 | 0.41 | 27187 |
| 2026-07-23 | NTRA | 264.56 | 0.82 | 1.83 | 27162 |
| 2026-07-24 | NTRA | 261.92 | 0.82 | 1.65 | 27176 |
| 2026-07-27 | NTRA | 258.23 | 0.83 | 0.10 | 27234 |
| 2026-07-28 | NTRA | 252 | 0.80 | 0.41 | 27806 |
| 2026-07-29 | NTRA | 253.17 | 0.79 | 4.33 | 28094 |
| 2026-07-30 | NTRA | 269.66 | 0.84 | 0.31 | 28242 |
| 2026-07-31 | NTRA | 264.69 | 0.84 | 0.30 | 28323 |
| 2026-08-03 | NTRA | 270.34 | 0.85 | 1.23 | 28431 |
| 2026-08-04 | NTRA | 275.15 | 0.85 | 1.66 | 28851 |
| 2026-08-05 | NTRA | 274.61 | 0.94 | 1.29 | 31516 |
| 2026-08-06 | NTRA | 265.06 | 0.95 | 3.29 | 32010 |
| 2026-08-07 | NTRA | 322.16 | 1.04 | 0.31 | 35855 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | NTRA | 271.92 | 28.7 | 5.4 | -1.70 |
| 2026-07-14 | NTRA | 272.80 | 28.7 | 7.6 | -1.70 |
| 2026-07-15 | NTRA | 277.44 | 28.7 | -9.2 | -1.70 |
| 2026-07-16 | NTRA | 269.88 | 28.7 | 3.9 | -1.70 |
| 2026-07-17 | NTRA | 271.47 | 27.8 | -5.8 | -1.71 |
| 2026-07-20 | NTRA | 262.97 | 27.8 | 5.1 | -1.71 |
| 2026-07-21 | NTRA | 267.32 | 27.8 | -9.3 | -1.71 |
| 2026-07-22 | NTRA | 264.27 | 27.8 | -0.8 | -1.71 |
| 2026-07-23 | NTRA | 264.78 | 27.8 | -4.6 | -1.71 |
| 2026-07-24 | NTRA | 261.99 | 27.8 | -1.0 | -1.71 |
| 2026-07-27 | NTRA | 258.21 | 27.8 | 0.2 | -1.71 |
| 2026-07-28 | NTRA | 251.98 | 27.8 | 2.8 | -1.71 |
| 2026-07-29 | NTRA | 253.80 | 27.8 | -5.9 | -1.71 |
| 2026-07-30 | NTRA | 269.77 | 27.8 | -22.4 | -1.71 |
| 2026-07-31 | NTRA | 267.77 | 27.8 | -2.0 | -1.71 |
| 2026-08-03 | NTRA | 270.42 | 27.8 | -6.9 | -1.71 |
| 2026-08-04 | NTRA | 270.42 | 27.8 | -6.9 | -1.71 |
| 2026-08-05 | NTRA | 274.38 | 27.8 | -3.2 | -1.71 |
| 2026-08-06 | NTRA | 265.61 | 27.8 | 5.3 | -1.71 |
| 2026-08-07 | NTRA | 322.42 | 27.8 | -66.9 | -1.71 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | NTRA | -12.75 | 1.67 | 4.25 |
| 2026-07-14 | NTRA | -12.75 | 1.67 | 4.25 |
| 2026-07-15 | NTRA | -12.80 | 1.67 | 4.25 |
| 2026-07-16 | NTRA | -12.84 | 1.67 | 4.25 |
| 2026-07-17 | NTRA | -12.84 | 1.67 | 4.25 |
| 2026-07-20 | NTRA | -12.86 | 1.58 | 4.25 |
| 2026-07-21 | NTRA | -12.86 | 1.58 | 4.25 |
| 2026-07-22 | NTRA | -12.86 | 1.58 | 4.25 |
| 2026-07-23 | NTRA | -10.36 | 1.58 | 4.25 |
| 2026-07-24 | NTRA | -10.36 | 1.58 | 4.25 |
| 2026-07-27 | NTRA | -10.36 | 1.57 | 3.63 |
| 2026-07-28 | NTRA | -10.34 | 1.57 | 3.63 |
| 2026-07-29 | NTRA | -10.34 | 1.57 | 3.63 |
| 2026-07-30 | NTRA | -10.36 | 1.57 | 3.63 |
| 2026-07-31 | NTRA | -10.36 | 1.57 | 3.63 |
| 2026-08-03 | NTRA | -10.36 | 1.42 | 3.63 |
| 2026-08-04 | NTRA | -10.36 | 1.42 | 3.63 |
| 2026-08-05 | NTRA | -8.99 | 1.42 | 3.63 |
| 2026-08-06 | NTRA | -9.11 | 1.42 | 3.63 |
| 2026-08-07 | NTRA | -9.11 | 1.42 | 3.63 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.6
Avg. EPS Est. Current Quarter
-0.53
Avg. EPS Est. Next Quarter
-0.38
Insider Transactions
-9.11
Institutional Transactions
1.42
Beta
1.5
Average Sales Estimate Current Quarter
661
Average Sales Estimate Next Quarter
694
Fair Value
191.54
Quality Score
49
Growth Score
58
Sentiment Score
67
Actual DrawDown %
-11.9
Max Drawdown 5-Year %
-77.7
Target Price
315.19
P/E
Forward P/E
PEG
P/S
17.04
P/B
25.4
P/Free Cash Flow
441.39
EPS
-1.37
Average EPS Est. Cur. Y
-1.71
EPS Next Y. (Est.)
-0.2
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-7.11
Relative Volume
2.23
Return on Equity vs Sector %
-40.1
Return on Equity vs Industry %
-24.2
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.03
EBIT Estimation
-66.9
◆
NTRA
Healthcare
$322.10
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
74.5
Range 1M
96%
Sup Dist
18.7%
Momentum Growth
Ride accelerating trends
WATCH
EPS Yr
9.9%
EPS NY
90.1%
52W%
98.3%
Long-Term Value
Quality companies, undervalued
WEAK
🔴 SELL
-25.1% upside
Upside
-25.1%
Quality
49
MoS
-41%
NTRA — P/E HistoricalDiagnostics & Research
Natera, Inc.Sector: Healthcare
Industry: Diagnostics & Research
Employees: 6135
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
NTRA
Latest News
—
Caricamento notizie per NTRA…
stock quote shares NTRA – Natera, Inc. Stock Price stock today
news today NTRA – Natera, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch NTRA – Natera, Inc. yahoo finance google finance
stock history NTRA – Natera, Inc. invest stock market
stock prices NTRA premarket after hours
ticker NTRA fair value insiders trading